接受帕妥珠单抗或安慰剂联合曲妥珠单抗和多西他赛治疗的晚期HER2阳性乳腺癌中肿瘤浸润淋巴细胞:CLEOPATRA研究的回顾性分析
CLEOPATRA研究的回顾性分析评估了晚期HER2阳性乳腺癌患者基线间质肿瘤浸润淋巴细胞(TIL)与生存的关系,共678例可评估。TIL每增加10%,总生存显著改善(校正HR 0.89),但无进展生存无显著关联。帕妥珠单抗疗效未因TIL水平而显著不同。
要点
- TIL每增加10%,总生存显著延长(校正HR 0.89,95%CI 0.83-0.96,p=0.0014)。
- TIL与无进展生存无显著关联(校正HR 0.95,95%CI 0.90-1.00,p=0.063)。
- 帕妥珠单抗疗效未因TIL水平而显著不同(交互作用PFS p=0.23,OS p=0.21)。
核心结论
- 在晚期HER2阳性乳腺癌患者中,较高的TIL值与总生存改善显著相关,提示抗肿瘤免疫效应延伸至晚期阶段。
研究设计与样本
- CLEOPATRA研究是一项随机3期试验,比较帕妥珠单抗或安慰剂联合曲妥珠单抗和多西他赛一线治疗局部复发、不可切除或转移性HER2阳性乳腺癌。
- 本分析为回顾性分析,评估了678例(84%)可评估患者的间质TIL,包括519例(77%)存档样本和155例(23%)新鲜样本(随机化前45天内采集)。
- 中位随访时间:无进展生存50个月(IQR 41-54),总生存51个月(IQR 46-57)。
主要发现
- 共发生519例无进展生存事件,358例患者死亡。
- TIL中位值为10%(IQR 5-30)。
- 新鲜肿瘤样本的TIL值显著低于存档样本(10.00% [95%CI 5.00-20.00] vs 15.00% [5.00-35.00];p=0.00036)。
- TIL每增加10%,总生存显著延长(校正HR 0.89,95%CI 0.83-0.96,p=0.0014)。
- TIL与无进展生存无显著关联(校正HR 0.95,95%CI 0.90-1.00,p=0.063)。
关键数值与推荐
- TIL以连续变量(每10%增量)纳入多因素Cox回归模型。
- 新鲜样本定义为随机化前45天或更短时间内采集。
临床怎么用
- 作者认为,未来该癌症亚型的临床研究应考虑将TIL作为分层因素,并研究增强免疫的疗法是否可能进一步改善生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel. METHODS: CLEOPATRA was a randomised phase 3 study comparing the addition of either pertuzumab or placebo to first-line therapy with trastuzumab and docetaxel for patients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer. We assessed the quantity of stromal TILs in prospectively collected tumour samples and investigated their association with progression-free survival, overall survival, clinicopathological characteristics, and pertuzumab treatment. We estimated hazard ratios (HR) and 95% CIs with multivariate Cox regression models fitting stromal TILs as a continuous variable (per 10% increment). The CLEOPATRA trial is registered with ClinicalTrials.gov, number NCT00567190. FINDINGS: Tumour samples from 678 (84%) of 808 participants were evaluable for TILs, including 519 (77%) archival samples, 155 (23%) freshly obtained samples (collected 45 days or fewer before randomisation), and four samples of unknown archival status. Median follow-up was 50 months (IQR 41-54) for progression-free survival and 51 months (IQR 46-57) for overall survival. 519 progression-free survival events occurred and 358 patients died. The median TIL value was 10% (IQR 5-30). Freshly obtained tumour samples had significantly lower TIL values than did archival samples (10·00% [95% CI 5·00-20·00] vs 15·00% [5·00-35·00]; p=0·00036). We detected no significant association between TIL values and progression-free survival (adjusted HR 0·95, 95% CI 0·90-1·00, p=0·063). However, for overall survival, each 10% increase in stromal TILs was significantly associated with longer overall survival (adjusted HR 0·89, 95% CI 0·83-0·96, p=0·0014). The treatment effect of pertuzumab did not differ significantly by stromal TIL value for either progression-free survival (pinteraction=0·23) or overall survival (pinteraction=0·21). INTERPRETATION: In patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significantly associated with improved overall survival, suggesting that the effect of antitumour immunity extends to the advanced setting. Future clinical studies in this cancer subtype should consider TILs as a stratification factor and investigate whether therapies that can augment immunity could potentially further improve survival. FUNDING: F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundation.
引用
- Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2016. PMID: 27964843. doi:10.1016/S1470-2045(16)30631-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。